
What is claimed is:

1. A compound represented by a formula:



or a pharmaceutically acceptable salt thereof;

wherein Ring A is an optionally substituted 10-membered heteroarylene having at least one ring nitrogen atom;

Ring B is an optionally substituted 6-membered arylene or an optionally substituted 6-membered heteroarylene containing at least one ring nitrogen atom;

Ring D is an optionally substituted 3, 4, 5, or 6-membered carbocycle or an optionally substituted 3, 4, 5, or 6-membered heterocycle;

L is -O-, -N(R^A)-, or -S(O)$_{0-2}$-;


X is -O-, or -N(R^B)-;

R^A, R^B and R^3 are independently H or C_{1-6} hydrocarbyl;

R^1 and R^2 are independently H, optionally substituted C_{1-12} alkyl, optionally substituted C_{6-10} aryl, optionally substituted C_{3-9} heteroaryl, or optionally substituted C_{3-6} cycloalkyl, wherein R^1 and R^2, together with the N atom to which they are attached, may form an optionally substituted cyclic ring, an optionally substituted bicyclic ring, or an optionally substituted bridged cyclic ring system; and when X is -N(R^B)-, R^1 and R^B may be linked, and together with the N atom to which R^1 is attached and the carbonyl group to which X is attached, may form an optionally substituted cyclic ring; and


R^4 and R^5 are independently H, an optionally substituted C_{1-12} hydrocarbyl, an optionally substituted C_{3-9} heteroaryl, or an optionally substituted C_{3-12} heterocycloalkyl, wherein R^4 and R^5, together with the nitrogen atom to which they are attached, may form an optionally substituted 4, 5, 6, or 7-membered heterocyclyl.

2. The compound of claim 1, wherein Ring A is further represented by a formula:



, wherein the structure is optionally substituted; wherein X is N, CH, or C(CN); and wherein the asterisk indicates the point of attachment of C atom to L.

3. The compound of claim 1, wherein Ring A is further represented by a formula:




, wherein the structure is optionally substituted; and wherein the asterisk indicates the point of attachment of C atom to L.

4. The compound of claim 2, wherein Ring A comprises optionally substituted 6-methoxy-quinolin-4,7-di-yl.

5. The compound of claim 3, wherein Ring A comprises optionally substituted 7-methoxy-quinolin-4,6-di-yl.

6. The compound of claim 1, wherein Ring B is further represented by a formula:



, wherein Y is N or C(R), wherein R is H, F, Cl, optionally substituted C_{1-6} hydrocarbyl, or optionally substituted O-C_{1-6} hydrocarbyl; and wherein the ring carbon atom at position 1 is directly attached to L.

7. The compound of claim 6, wherein Y is C(R), and wherein R is H, F, or optionally substituted C_{1-3} alkyl.

8. The compound of claim 1, wherein Ring D is an optionally substituted cyclopropane-1,1-di-yl.

9. The compound of claim 1, wherein L is -O-.

10. The compound of claim 1, wherein R^3 is H.

11. The compound of claim 1, wherein -N(R^1)(R^2) is optionally substituted (R)-2,4-dimethylpiperazin-1-yl.

12. The compound of claim 1, wherein -N(R^1)(R^2) is optionally substituted (S)-2,4-dimethylpiperazin-1-yl.

13. The compound of claim 1, wherein -N(R^1)(R^2) is optionally substituted 4-methylpiperazin-1-yl.

14. The compound of claim 1, wherein -N(R^1)(R^2) is optionally substituted (R)-2-methylpiperazin-1-yl.

15. The compound of claim 1, wherein -N(R^1)(R^2) is optionally substituted 2-oxoimidazolidin-1-yl.

16. The compound of claim 1, wherein R^5 is H.


17. The compound of claim 1, wherein R^6 is 4-fluorophenyl.


18. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl piperazine-1-carboxylate, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl piperidine-1-carboxylate, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl pyrrolidine-1-carboxylate, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl carbamate, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl 2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl morpholine-4-carboxylate, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl (1R,4R)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl (1S,4S)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate, optionally substituted N-(4-((7-(2-oxoimidazolidin-1-yl)quinolin-4-yl)oxy)phenyl)-N-phenylcyclopropane-1,1-dicarboxamide, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-6-yl piperazine-1-carboxylate, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinazolin-7-yl piperazine-1-carboxylate, or optionally substituted 4-


(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl (1R,5S)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate.


19. The compound of claim 1, wherein the compound is deuterated.


20. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is:


,



,


,



,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,








,




,




,



,

,

,

,

,




,




,








,




,




,



,

,

,

,

,




,




,



,



, or



.

21. Use of a compound of claim 1 in the manufacture of a medicament for treating cancer, an infectious disease, another kinase-related disease or disorder, or a combination thereof, wherein the use comprise that the compound is to be administered to a mammal in need thereof.